UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of August 2025
001-36345
(Commission
File Number)
GALMED
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
c/o
Meitar Law Offices Abba Hillel Silver Rd.,
Ramat
Gan, 5250608
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
On
August 15, 2025, Galmed Pharmaceuticals Ltd. (the “Company”) held a Special
General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company’s shareholders voted on the proposal described
in the proxy statement for the Meeting included as an exhibit to the Company’s report on Form 6-K furnished by the Company with
the Securities and Exchange Commission on July 24, 2025. The proposal brought before the shareholders at the Meeting was approved by
the shareholders of the Company with the requisite majority in accordance with the Israeli Companies Law, 5759-1999.
A
copy of the Company’s amended and restated articles of association, approved by shareholders at the Meeting, is attached hereto
as Exhibit 99.1.
This
Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441,
and 333-284163) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).
EXHIBIT
INDEX
| Exhibit
No. |
|
Description |
| |
|
|
| 99.1 |
|
Amended and Restated Articles of Association |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Galmed
Pharmaceuticals Ltd. |
| |
|
|
| Date:
August 15, 2025 |
By: |
/s/
Allen Baharaff |
| |
|
Allen
Baharaff |
| |
|
President
and Chief Executive Officer |
